RESUMO
BACKGROUND: Psoriasis is a chronic, inflammatory, relapsing and remitting disease with no cure till date. There is a paucity of trials using a combination of methotrexate (MTX) and cyclosporine (CsA) in chronic plaque psoriasis, due to fear of added toxicity, although they are time tested treatment options for monotherapy. AIMS: The study aimed to compare the efficacy and adverse effect profile of the standard recommended dose of MTX (i.e. 0.3mg/kg/week) versus a combination of reduced doses of MTX and CsA (i.e. MTX 0.15 mg/kg/week with CsA 2.5mg/kg/day) in patients with chronic plaque psoriasis. METHODS: Study design was a non-blinded randomised controlled trial. Patients of chronic plaque psoriasis with PASI more than 10 were randomised in 1: 1 allocation to receive either 0.3 mg/kg/week of intramuscular MTX injection or a combination of 0.15 mg/kg/week of intramuscular MTX injection and 2.5 mg/kg/day of CsA rounded off to the nearest 25 mg. Patients were followed up at every 2 weeks for 12 weeks. The doses were kept fixed throughout the study period. RESULTS: A total of 66 patients received MTX monotherapy, whereas 67 patients received the combination. At baseline, both groups were comparable in their BSA (P = 0.105, Student t-test) and PASI (P = 0.277, Student t-test), which reduced significantly at 12 weeks in both groups (P < 0.001, paired t-test). The achievement of PASI-75 (P = 0.005), PASI-90 (P < 0.001) and PASI-100 (P = 0.001) was more in the combination group (Chi square test). Intention to treat analysis using Chi square test also showed better outcomes for PASI-75 (P = 0.027), PASI-90 (P < 0.001) and PASI-100 (P = 0.001) in the combination group. Combination group also had earlier onset of action (P = 0.001, Chi square test). There was no significant difference between the groups in terms of laboratory and clinical adverse events. LIMITATIONS: Non-blinded, no comparison with CsA monotherapy arm, no follow up beyond 12 weeks. CONCLUSION: The combination of reduced doses of MTX and CsA is more efficacious with earlier onset of action and similar adverse effects as with MTX monotherapy.
Assuntos
Ciclosporina/administração & dosagem , Fármacos Dermatológicos/administração & dosagem , Metotrexato/administração & dosagem , Psoríase/tratamento farmacológico , Administração Oral , Adulto , Quimioterapia Combinada , Feminino , Humanos , Injeções Intramusculares , Masculino , Índice de Gravidade de DoençaRESUMO
BACKGROUND: Autologous serum therapy aims to supplement the existing pharmacotherapy in chronic urticaria by decreasing the antihistamine pill-burden and maintaining symptom-free interval. Subcutaneous autologous serum therapy further modifies the amount of serum (2 mL to 1 mL) and gauge of a needle (24G to 31G) to improve compliance and facilitate ease of application. OBJECTIVES: To assess clinical effectiveness and safety of subcutaneous autologous serum therapy versus conventional intramuscular autologous serum therapy and to compare the quality of life in the two treatment arms. METHODS: Institution-based, assessor-blind, prospective, randomized, parallel-group, active-controlled trial with 32 patients in each treatment arm and analyzed on a modified intention to treat principle. After baseline autologous serum skin test, autologous serum was injected as per randomization every week for 9 consecutive weeks. RESULTS: Among the study population, conventional intramuscular autologous serum therapy and subcutaneous autologous serum therapy had a comparable duration of disease (P = 0.164, Mann-Whitney U test), autoreactive status (P = 0.796), urticaria total severity score (P = 0.637) and urticaria activity score summed up over 7 days (P = 0.982). Both urticaria activity score summed up over 7 days and total severity score along with antihistamine pill-burden reduced significantly (P < 0.001, Friedman's analysis of variance) in both subcutaneous autologous serum therapy and conventional intramuscular autologous serum therapy from first follow-up onwards (P < 0.05, Post hoc Dunn's test). Significant improvement was noted in patient's as well as physician's global assessment of disease activity improvement scale (P < 0.001, Friedman's analysis of variance). Intergroup analysis showed that there was no significant difference in urticaria activity score summed up over 7 days either at baseline (P = 0.982, Mann-Whitney U test) or at study end (P = 0.398, Mann-Whitney U test). Similar comparable results were found in the total severity score at the end of the study (P = 0.345, Mann-Whitney U test). Dermatology life quality index showed marked improvement with both types of treatment (P < 0.0001, Wilcoxon test), and the intergroup comparison showed comparable dermatology life quality index values (P = 0.994, Mann-Whitney U test). The pain score at the injection site was more with conventional intramuscular autologous serum therapy than subcutaneous autologous serum therapy (P = 0.0115, Mann-Whitney test). Younger age and lower baseline total severity scores were associated with a better therapeutic response. Baseline urticaria activity score added up over a period of 7 days and total severity scores and the diameter of lesions showed a positive correlation with response pattern. LIMITATION: Basophil histamine release assay not done. Logistics could not support follow-up beyond the end of treatment. CONCLUSION: Subcutaneous autologous serum therapy is not inferior to conventional intramuscular autologous serum therapy with the additional advantage of less pain and operational feasibility.
Assuntos
Transfusão de Sangue Autóloga/métodos , Urticária Crônica/terapia , Soro/imunologia , Adulto , Feminino , Humanos , Injeções Intramusculares , Injeções Subcutâneas , Masculino , Pessoa de Meia-Idade , Método Simples-Cego , Resultado do Tratamento , Adulto JovemRESUMO
Healthy United States-based adult volunteers with no history of travel to leprosy-endemic countries were enrolled for the first-in-human evaluation of LepVax (LEP-F1 + GLA-SE). In total 24 volunteers participated in an open-labelclinicaltrial, with 21 receiving three injections of LepVax consisting of either 2 µg or 10 µg recombinantpolyprotein LEP-F1 mixed with 5 µg of the GLA-SE adjuvant formulation. LepVax doses were provided by intramuscular injection on Days 0, 28, and 56, and safety was evaluated for one year following the final injection. LepVaxwas safe and well tolerated at both antigen doses. Immunological analyses indicated that similar LEP-F1-specific antibody and Th1 cytokine secretion (IFN-γ, IL-2, TNF) were induced by each of the antigen doses evaluated within LepVax. This clinicaltrialof the first definedvaccinecandidate for leprosy demonstrates that LepVax is safe and immunogenic in healthy subjects and supports its advancement to testing in leprosy-endemic regions.
Assuntos
Vacinas Bacterianas/imunologia , Imunogenicidade da Vacina , Hanseníase/prevenção & controle , Adjuvantes Imunológicos/administração & dosagem , Adulto , Anticorpos Antibacterianos/sangue , Formação de Anticorpos , Vacinas Bacterianas/efeitos adversos , Citocinas/imunologia , Relação Dose-Resposta Imunológica , Humanos , Injeções Intramusculares , Mycobacterium lepraeAssuntos
Infecções por HIV/complicações , Sífilis/diagnóstico , Terapia Antirretroviral de Alta Atividade , Biópsia , Diagnóstico Diferencial , Infecções por HIV/tratamento farmacológico , Humanos , Injeções Intramusculares , Hanseníase Tuberculoide , Masculino , Pessoa de Meia-Idade , Penicilina G Benzatina/administração & dosagem , Penicilina G Benzatina/uso terapêutico , Sífilis/tratamento farmacológico , Resultado do TratamentoAssuntos
Mãos/patologia , Infecções/patologia , Reação no Local da Injeção/patologia , Dor/patologia , Prototheca/isolamento & purificação , Esteroides/efeitos adversos , Feminino , Mãos/microbiologia , Humanos , Infecções/terapia , Reação no Local da Injeção/microbiologia , Reação no Local da Injeção/terapia , Injeções Intramusculares/efeitos adversos , Pessoa de Meia-Idade , Dor/microbiologia , Esteroides/administração & dosagemAssuntos
Acne Vulgar/induzido quimicamente , Acne Vulgar/diagnóstico , Paralisia Facial/diagnóstico , Paralisia Facial/tratamento farmacológico , Glucocorticoides/efeitos adversos , Adulto , Dexametasona/administração & dosagem , Dexametasona/efeitos adversos , Feminino , Glucocorticoides/administração & dosagem , Humanos , Injeções Intramusculares , Masculino , Metilprednisolona/administração & dosagem , Metilprednisolona/efeitos adversosAssuntos
Neoplasias Faciais/complicações , Neoplasias Faciais/diagnóstico , Leishmaniose Mucocutânea/complicações , Leishmaniose Mucocutânea/diagnóstico , Face/patologia , Neoplasias Faciais/tratamento farmacológico , Humanos , Injeções Intramusculares , Leishmaniose Mucocutânea/tratamento farmacológico , Masculino , Meglumina/administração & dosagem , Antimoniato de Meglumina , Pessoa de Meia-Idade , Compostos Organometálicos/administração & dosagemRESUMO
Leprosy caused by Mycobacterium leprae primarily affects the skin and peripheral nerves. As a human infectious disease, it is still a significant health and economic burden on developing countries. Although multidrug therapy is reducing the number of active cases to approximately 0.5 million, the number of cases per year is not declining. Therefore, alternative host-directed strategies should be addressed to improve treatment efficacy and outcome. In this work, using murine leprosy as a model, a very similar granulomatous skin lesion to human leprosy, we have found that successive IFN-alpha boosting protects BCG-vaccinated mice against M. lepraemurium infection. No difference in the seric isotype and all IgG subclasses measured, neither in the TH1 nor in the TH2 type cytokine production, was seen. However, an enhanced iNOS/NO production in BCG-vaccinated/i.m. IFN-alpha boosted mice was observed. The data provided in this study suggest a promising use for IFN-alpha boosting as a new prophylactic alternative to be explored in human leprosy by targeting host innate cell response.
Assuntos
Vacina BCG/uso terapêutico , Interferon-alfa/uso terapêutico , Infecções por Mycobacterium/tratamento farmacológico , Infecções por Mycobacterium/prevenção & controle , Mycobacterium lepraemurium , Animais , Vacina BCG/administração & dosagem , Injeções Intramusculares , Interferon-alfa/administração & dosagem , CamundongosAssuntos
Antibacterianos/efeitos adversos , Gentamicinas/efeitos adversos , Síndrome de Nicolau/etiologia , Antibacterianos/administração & dosagem , Nádegas , Gentamicinas/administração & dosagem , Humanos , Injeções Intramusculares , Perna (Membro) , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Síndrome de Nicolau/patologia , Coxa da PernaRESUMO
BACKGROUND: Surgical debridement was the standard treatment for Mycobacterium ulcerans infection (Buruli ulcer disease) until WHO issued provisional guidelines in 2004 recommending treatment with antimicrobial drugs (streptomycin and rifampicin) in addition to surgery. These recommendations were based on observational studies and a small pilot study with microbiological endpoints. We investigated the efficacy of two regimens of antimicrobial treatment in early-stage M ulcerans infection. METHODS: In this parallel, open-label, randomised trial undertaken in two sites in Ghana, patients were eligible for enrolment if they were aged 5 years or older and had early (duration <6 months), limited (cross-sectional diameter <10 cm), M ulcerans infection confirmed by dry-reagent-based PCR. Eligible patients were randomly assigned to receive intramuscular streptomycin (15 mg/kg once daily) and oral rifampicin (10 mg/kg once daily) for 8 weeks (8-week streptomycin group; n=76) or streptomycin and rifampicin for 4 weeks followed by rifampicin and clarithromycin (7.5 mg/kg once daily), both orally, for 4 weeks (4-week streptomycin plus 4-week clarithromycin group; n=75). Randomisation was done by computer-generated minimisation for study site and type of lesion (ulceration or no ulceration). The randomly assigned allocation was sent from a central site by cell-phone text message to the study coordinator. The primary endpoint was lesion healing at 1 year after the start of treatment without lesion recurrence or extensive surgical debridement. Analysis was by intention-to-treat. This trial is registered with ClinicalTrials.gov, number NCT00321178. FINDINGS: Four patients were lost to follow-up (8-week streptomycin, one; 4-week streptomycin plus 4-week clarithromycin, three). Since these four participants had healed lesions at their last assessment, they were included in the analysis for the primary endpoint. 73 (96%) participants in the 8-week streptomycin group and 68 (91%) in the 4-week streptomycin plus 4-week clarithromycin group had healed lesions at 1 year (odds ratio 2.49, 95% CI 0.66 to infinity; p=0.16, one-sided Fisher's exact test). No participants had lesion recurrence at 1 year. Three participants had vestibulotoxic events (8-week streptomycin, one; 4-week streptomycin plus 4-week clarithromycin, two). One participant developed an injection abscess and two participants developed an abscess close to the initial lesion, which was incised and drained (all three participants were in the 4-week streptomycin plus 4-week clarithromycin group). INTERPRETATION: Antimycobacterial treatment for M ulcerans infection is effective in early, limited disease. 4 weeks of streptomycin and rifampicin followed by 4 weeks of rifampicin and clarithromycin has similar efficacy to 8 weeks of streptomycin and rifampicin; however, the number of injections of streptomycin can be reduced by switching to oral clarithromycin after 4 weeks. FUNDING: European Union (EU FP6 2003-INCO-Dev2-015476) and Buruli Ulcer Groningen Foundation.
Assuntos
Antibacterianos/uso terapêutico , Úlcera de Buruli/tratamento farmacológico , Claritromicina/uso terapêutico , Hansenostáticos/uso terapêutico , Mycobacterium ulcerans/efeitos dos fármacos , Estreptomicina/uso terapêutico , Administração Oral , Adolescente , Adulto , Úlcera de Buruli/diagnóstico , Criança , Esquema de Medicação , Quimioterapia Combinada , Determinação de Ponto Final , Feminino , Seguimentos , Gana , Humanos , Injeções Intramusculares , Masculino , Mycobacterium ulcerans/isolamento & purificação , Rifampina/uso terapêutico , Estatísticas não Paramétricas , Fatores de Tempo , Resultado do Tratamento , Adulto JovemRESUMO
We previously reported that a DNA vaccine constructed with the heat shock protein (HSP65) gene from Mycobacterium leprae (DNA-HSP65) was protective and also therapeutic in experimental tuberculosis. By the intramuscular route, this vaccine elicited a predominant Th1 response that was consistent with its protective efficacy against tuberculosis. It has been suggested that the immune response to Hsp60/65 may be the link between exposure to microorganisms and increased cardiovascular risk. Additionally, the high cholesterol levels found in atherosclerosis could modulate host immunity. In this context, we evaluated if an atherogenic diet could modulate the immune response induced by the DNA-HSP65 vaccine. C57BL/6 mice (4-6 animals per group) were initially submitted to a protocol of atherosclerosis induction and then immunized by the intramuscular or intradermal route with 4 doses of 100 mug DNA-HSP65. On day 150 (15 days after the last immunization), the animals were sacrificed and antibodies and cytokines were determined. Vaccination by the intramuscular route induced high levels of anti-Hsp65 IgG2a antibodies, but not anti-Hsp65 IgG1 antibodies and a significant production of IL-6, IFN-g and IL-10, but not IL-5, indicating a Th1 profile. Immunization by the intradermal route triggered a mixed pattern (Th1/Th2) characterized by synthesis of anti-Hsp65 IgG2a and IgG1 antibodies and production of high levels of IL-5, IL-6, IL-10, and IFN-g. These results indicate that experimentally induced atherosclerosis did not affect the ability of DNA-HSP65 to induce a predominant Th1 response that is potentially protective against tuberculosis.
Assuntos
Animais , Feminino , Camundongos , Aterosclerose/imunologia , Proteínas de Bactérias/imunologia , Chaperoninas/imunologia , Células Th1/imunologia , Vacinas contra a Tuberculose/imunologia , Vacinas de DNA/imunologia , Autoanticorpos/sangue , Autoanticorpos/imunologia , Proteínas de Bactérias/administração & dosagem , Chaperoninas/administração & dosagem , Citocinas/sangue , Citocinas/imunologia , Dieta Aterogênica , Injeções Intradérmicas , Injeções Intramusculares , Imunoglobulina G/sangue , Imunoglobulina G/imunologia , Organismos Livres de Patógenos Específicos , Vacinas contra a Tuberculose/administração & dosagem , Tuberculose/imunologia , Tuberculose/prevenção & controle , Vacinas de DNA/administração & dosagemRESUMO
We previously reported that a DNA vaccine constructed with the heat shock protein (HSP65) gene from Mycobacterium leprae (DNA-HSP65) was protective and also therapeutic in experimental tuberculosis. By the intramuscular route, this vaccine elicited a predominant Th1 response that was consistent with its protective efficacy against tuberculosis. It has been suggested that the immune response to Hsp60/65 may be the link between exposure to microorganisms and increased cardiovascular risk. Additionally, the high cholesterol levels found in atherosclerosis could modulate host immunity. In this context, we evaluated if an atherogenic diet could modulate the immune response induced by the DNA-HSP65 vaccine. C57BL/6 mice (4-6 animals per group) were initially submitted to a protocol of atherosclerosis induction and then immunized by the intramuscular or intradermal route with 4 doses of 100 microg DNA-HSP65. On day 150 (15 days after the last immunization), the animals were sacrificed and antibodies and cytokines were determined. Vaccination by the intramuscular route induced high levels of anti-Hsp65 IgG2a antibodies, but not anti-Hsp65 IgG1 antibodies and a significant production of IL-6, IFN-g and IL-10, but not IL-5, indicating a Th1 profile. Immunization by the intradermal route triggered a mixed pattern (Th1/Th2) characterized by synthesis of anti-Hsp65 IgG2a and IgG1 antibodies and production of high levels of IL-5, IL-6, IL-10, and IFN-g. These results indicate that experimentally induced atherosclerosis did not affect the ability of DNA-HSP65 to induce a predominant Th1 response that is potentially protective against tuberculosis.
Assuntos
Aterosclerose/imunologia , Proteínas de Bactérias/imunologia , Chaperoninas/imunologia , Células Th1/imunologia , Vacinas contra a Tuberculose/imunologia , Vacinas de DNA/imunologia , Animais , Autoanticorpos/sangue , Autoanticorpos/imunologia , Proteínas de Bactérias/administração & dosagem , Chaperonina 60 , Chaperoninas/administração & dosagem , Citocinas/sangue , Citocinas/imunologia , Dieta Aterogênica , Feminino , Imunoglobulina G/sangue , Imunoglobulina G/imunologia , Injeções Intradérmicas , Injeções Intramusculares , Camundongos , Camundongos Endogâmicos C57BL , Organismos Livres de Patógenos Específicos , Tuberculose/imunologia , Tuberculose/prevenção & controle , Vacinas contra a Tuberculose/administração & dosagem , Vacinas de DNA/administração & dosagemRESUMO
BACKGROUND: Intralesional sodium stibogluconate (SSG) has become first line therapy for localized cutaneous leishmaniasis (LCL). AIMS: This study compares the efficacy of intralesional SSG given alone with that of intralesional SSG combined with intramuscular SSG. METHODS: Thirty-two patients aged between 5-56 years were included in the study. The first group received three injections of intralesional SSG on alternate days while the other group received three injections of intralesional SSG similar to the first group and the rest of the calculated dose as a simultaneous, intramuscular injection. Patients were followed up every four weeks to assess for cure/ the need for repeating the treatment. RESULTS: Five patients from group 1 having small nodular lesions of < six months duration were cured after 1-2 treatment cycles. However, six patients with mucosal lesions, large lesions and lesions of > six months duration needed 3-5 treatment schedules. Most plaques and mucosal lesions in seven patients in group 2 cleared with two treatment cycles. CONCLUSION: Intralesional combined with intramuscular SSG appears more effective in LCL and gave qualitatively superior healing than intralesional SSG given alone.
Assuntos
Gluconato de Antimônio e Sódio/administração & dosagem , Antiprotozoários/administração & dosagem , Leishmaniose Cutânea/tratamento farmacológico , Pele/patologia , Adolescente , Adulto , Criança , Pré-Escolar , Esquema de Medicação , Feminino , Humanos , Injeções Intralesionais , Injeções Intramusculares , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Pele/parasitologia , Resultado do TratamentoRESUMO
A 36-year-old HIV1-positive woman presented with a 6-month history of a progressive papular and nodular eruption of the face and subsequent extensive spread to the rest of the skin. The diagnosis of diffuse cutaneous leishmaniasis was established by direct examination and skin biopsy. This atypical form had a dramatic improvement after a 21-day treatment with meglumine antimoniate. This clinical form may be confused with other endemic diseases in western Africa, especially leprosy.
Assuntos
Dermatoses Faciais/diagnóstico , Infecções por HIV , Leishmaniose Tegumentar Difusa/diagnóstico , África Ocidental , Antiprotozoários/administração & dosagem , Antiprotozoários/uso terapêutico , Diagnóstico Diferencial , Dermatoses Faciais/tratamento farmacológico , Dermatoses Faciais/patologia , Feminino , Humanos , Injeções Intramusculares , Leishmaniose Tegumentar Difusa/tratamento farmacológico , Leishmaniose Tegumentar Difusa/patologia , Meglumina/administração & dosagem , Meglumina/uso terapêutico , Antimoniato de Meglumina , Pessoa de Meia-Idade , Compostos Organometálicos/administração & dosagem , Compostos Organometálicos/uso terapêuticoRESUMO
A large spectrum of clinical presentations of cutaneous leishmaniasis (CL) have been reported including a scar presentation in many chronic cases. We report here a case where CL developed in a scar of healed lesion of tuberculoid leprosy. Initially, it was suspected as a relapse or reaction of the previous disease, but on histopathology, it proved to be a new disease (CL). On anti-leishmaniasis treatment, lesion healed satisfactorily in about a month time.
Assuntos
Cicatriz/complicações , Úlcera da Perna/etiologia , Leishmaniose Cutânea/etiologia , Hanseníase Tuberculoide/complicações , Adulto , Animais , Cicatriz/diagnóstico , Seguimentos , Humanos , Injeções Intramusculares , Úlcera da Perna/tratamento farmacológico , Úlcera da Perna/fisiopatologia , Leishmaniose Cutânea/tratamento farmacológico , Leishmaniose Cutânea/fisiopatologia , Hanseníase Tuberculoide/diagnóstico , Hanseníase Tuberculoide/tratamento farmacológico , Masculino , Meglumina/uso terapêutico , Medição de Risco , Índice de Gravidade de Doença , Resultado do Tratamento , CicatrizaçãoRESUMO
Past attempts to use fractions of mycobacteria as an alternative to BCG have given disappointing results. The availability of cloned genes and suitable vectors has now opened a new avenue in which individual mycobacterial protein antigens are synthesised within transfected mammalian cells. In an ex vivo transfection approach with a retroviral vector we found that even a single antigen (hsp65) could evoke strong protection when expressed as a transgene and that expression of protection was largely a function of antigen specific cytotoxic T cells. We now find that intramuscular injection of plasmid DNA expressing the antigen from either a viral or a murine promoter can also give protection equivalent to Bacillus Calmette-Guérin (BCG). Plasmids expressing some other mycobacterial antigens, hsp70, 36 kDa and 6 kDa, are also effective, suggesting that this approach may lead to a new vaccine.
Assuntos
Vacina BCG/imunologia , Proteínas de Bactérias , Tuberculose/prevenção & controle , Vacinas de DNA/imunologia , Animais , Anticorpos Antibacterianos/biossíntese , Antígenos de Bactérias/genética , Antígenos de Bactérias/imunologia , Vacina BCG/genética , Chaperonina 60 , Chaperoninas/genética , Chaperoninas/imunologia , Células Clonais/imunologia , Injeções Intramusculares , Interferon gama/biossíntese , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos CBA , Mycobacterium leprae/genética , Mycobacterium leprae/imunologia , Plasmídeos/genética , Plasmídeos/imunologia , Linfócitos T Citotóxicos/imunologia , Vacinas de DNA/administração & dosagemRESUMO
Intradermal administration of recombinant interferon gamma (rIFN-gamma) to lepromatous leprosy patients has converted the local histology toward a tuberculoid pattern. However, such changes have been confined to the site of injection. In contrast, in the present study, marked, intradermal accumulation of CD3+, CD4+, CD8+, and CD1a+ T cells and Leu-M5+ mononuclear phagocytes was induced at a distance from the sites of administration, in a dose-dependent manner, by 10 daily intramuscular injections of 10-30 micrograms rIFN-gamma/m2. Mononuclear cell infiltration began within 3 d of onset of rIFN-gamma therapy and persisted at least 8 wk. Intramuscular administration of rIFN-gamma to lepromatous patients receiving concurrent chemotherapy can safely induce widespread histologic features of an upgrading reaction.